Valacyclovir
Treatment for Varicella and herpes zoster
Typical Dosage: 1000mg three times daily for 7 days
Effectiveness
88%
Safety Score
68%
Clinical Trials
13
Participants
20K
Comparative Safety Scale(Higher is safer)
Cyanideβ οΈ
Methπ
Cigarettesπ¬
Chemoβ’οΈ
AlcoholπΊ
Morphineπ
Antibioticsπ
Tylenolπ
Exerciseπ
Waterπ§
68
DangerousModerateSafe
Treatment Details
Dosage Range
1000mg three times daily for 7 days
Time to Effect
24-48 hours
Treatment Duration
7 days
Evidence Quality
HIGHNumber Needed to Treat (NNT)
12(Treat 12 patients to see 1 additional successful outcome)
Number Needed to Harm (NNH)
1000(Treat 1000 patients to see 1 additional serious adverse event)
Confidence Score
90%confidence in effectiveness data
Health Economics
Annual Cost of Care
Drug Cost:$40
Monitoring:$100
Side Effect Mgmt:$10
Total Annual:$150
Cost-Effectiveness Analysis
Cost-Effectiveness Rating
GOODQALYs Gained
0.04
Outcome-Based Costs
Cost per Responder
$200
Cost per Remission
$167
Comparison vs Acyclovir
Cost Difference
+$10/year
More expensive
QALY Difference
+0.01 QALYs
Better outcomes
Dominance
No dominance
Valacyclovir Outcomes
for Varicella and herpes zoster
Efficacy Outcomes
Overall Effectiveness
+88%
Response Rate
+75%
Remission Rate
+90%
Common Side Effects
Nausea
+15%
Headache
+15%
Abdominal pain
+6%
Diarrhea
+5%
WARNING: LIMITED TRIALS AVAILABLE
You can search for trials, but you probably can't join any because the 1% Treaty hasn't passed yet. Most trials are severely limited by lack of funding and bureaucratic barriers. Help change this!
Active Clinical Trials
No active trials currently recruiting for this treatment
No active trials found in ClinicalTrials.gov
Completed Clinical Trials
9 completed trials for Valacyclovir in Varicella and herpes zoster
A Phase 2b Trial of EPB-348 for the Treatment of Herpes Zoster
NCT00831103COMPLETEDPHASE2
373 participants
INTERVENTIONAL
Houston, United States
Started: Nov 1, 2007
A Study Exploring Efficacy of Peginterferon in Patients With Herpes Zoster
NCT05492591COMPLETEDPHASE2
50 participants
INTERVENTIONAL
Nanjing, China
Started: Oct 11, 2022
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fed Conditions
NCT01132716COMPLETEDNA
48 participants
INTERVENTIONAL
Fargo, United States
Started: Sep 1, 2006
Bioequivalency Study of Valacyclovir Hydrochloride 1000 mg Under Fasting Conditions
NCT01132729COMPLETEDNA
48 participants
INTERVENTIONAL
Fargo, United States
Started: Sep 1, 2006
Palatability Testing of a New Paediatric Formulation of Valacyclovir
NCT01682109COMPLETEDPHASE4
41 participants
INTERVENTIONAL
Nijmegen, Netherlands
Started: Sep 1, 2012
Bioequivalence Study in Healthy Volunteers of a New Paediatric Formulation of Valacyclovir
NCT01689285COMPLETEDPHASE1
16 participants
INTERVENTIONAL
Nijmegen, Netherlands
Started: Dec 1, 2013
Reduction of Postherpetic Neuralgia in Herpes Zoster
NCT01250561COMPLETEDNA
133 participants
INTERVENTIONAL
Houston, United States
Started: Feb 1, 2002
A Safety And Tolerability Study Of Valaciclovir Oral Suspension In Infants And Children
NCT00297206COMPLETEDPHASE1
36 participants
INTERVENTIONAL
Birmingham, United States +12 more
Started: Jan 25, 2003
Ultrasound-Guided Thoracic Paravertebral Block With Steroid and Local Anesthetic for Acute Herpes Zoster: Effects on Pain Control and Prevention of Postherpetic Neuralgia
NCT07349680COMPLETEDPHASE3
100 participants
INTERVENTIONAL
Asyut, Egypt
Started: Mar 15, 2023